Ranked India-based API manufacturers
01 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 3 active US DMFs and 3 valid CEPs for rosuvastatin, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
29 markets
02 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and 3 valid CEPs for rosuvastatin, filing since 2007. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
26 markets
03 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and 4 valid CEPs for rosuvastatin, filing since 2014. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
29 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and one valid CEP for rosuvastatin, filing since 2020. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 6 markets.
Last FDA inspection
2025 · NAI
GMP recognised in
6 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs and 4 valid CEPs for rosuvastatin, filing since 2018. Its 2023 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Last FDA inspection
2023 · NAI
GMP recognised in
2 markets
06 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs and one valid CEP for rosuvastatin, filing since 2021. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 14 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
14 markets
07 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and one valid CEP for rosuvastatin, filing since 2020. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
4 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 4 active US DMFs and 4 valid CEPs for rosuvastatin, filing since 2007. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Last FDA inspection
2025 · NAI
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and 3 valid CEPs for rosuvastatin, filing since 2022. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Last FDA inspection
2022 · VAI
GMP recognised in
1 markets
Holds one active US DMF and one valid CEP for rosuvastatin, filing since 2023. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Last FDA inspection
2024 · VAI
GMP recognised in
1 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF and 2 valid CEPs for rosuvastatin, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Last FDA inspection
2025 · VAI
GMP recognised in
1 markets
12 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for rosuvastatin, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
6 markets
13 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for rosuvastatin, filing since 2013. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 30 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
30 markets
Holds one valid CEP for rosuvastatin, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
6 markets
Credentials confirmed against the regulator files on 25 July 2026
Holds 2 active US DMFs for rosuvastatin, filing since 2018. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Last FDA inspection
2024 · VAI
GMP recognised in
3 markets
16 India
Makes the APIFinished dose
Credentials confirmed against the regulator files on 25 July 2026
Holds one active US DMF for rosuvastatin, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Last FDA inspection
2025 · VAI
GMP recognised in
25 markets
13 more manufacturers in India hold filings for rosuvastatin
The names are listed below. The filings, inspection history and GMP certificates behind
each one are available with a free account.
Open the full list with a free account How this list is built
This page filters the worldwide Rosuvastatin manufacturer list to
companies based in India. The order is set by active filings weighted by regulator,
inspection outcomes and their recency, breadth of GMP recognition, and evidence of real
exports, less any open risk flags.
Read the full method.